FR2750332A1 - Topical skin composition to treat or prevent cellulite - Google Patents
Topical skin composition to treat or prevent cellulite Download PDFInfo
- Publication number
- FR2750332A1 FR2750332A1 FR9608122A FR9608122A FR2750332A1 FR 2750332 A1 FR2750332 A1 FR 2750332A1 FR 9608122 A FR9608122 A FR 9608122A FR 9608122 A FR9608122 A FR 9608122A FR 2750332 A1 FR2750332 A1 FR 2750332A1
- Authority
- FR
- France
- Prior art keywords
- composition according
- extract
- thiol
- weight
- cellulite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 11
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 11
- 230000036232 cellulite Effects 0.000 title claims abstract description 11
- 230000000699 topical effect Effects 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 22
- 150000003573 thiols Chemical class 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 8
- 244000194101 Ginkgo biloba Species 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 230000004089 microcirculation Effects 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 230000004130 lipolysis Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 241001119526 Paullinia Species 0.000 claims description 4
- 235000010242 Paullinia Nutrition 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 244000215554 Nepeta hederacea Species 0.000 claims description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
- 235000014043 Glechoma hederacea var parviflora Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960001639 penicillamine Drugs 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 241000125175 Angelica Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 241001072382 Glechoma Species 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 241000978499 Brunnichia ovata Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000213996 Melilotus Species 0.000 description 1
- 235000000839 Melilotus officinalis subsp suaveolens Nutrition 0.000 description 1
- 235000011755 Nepeta hederacea Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 241000605385 Ruscus Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002995 comedolytic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
La présente invention concerne des compositions cosmétiques ou pharmaceutiques permettant la prévention et le traitement des désordres esthétiques et/ou physiopathologiques plus connus dans le langage commun sous la dénomination de cellulite. The present invention relates to cosmetic or pharmaceutical compositions for the prevention and treatment of aesthetic and / or pathophysiological disorders better known in common parlance under the name of cellulite.
L'entité clinique appelée cellulite est avant tout considérée comme une conséquence de modifications polyendocriniennes. La pathogénie semble liée à une hyperpolymérisation des mucopolysaccharides et à une rétention hydrique, conduisant à une hyperviscosité de la substance fondamentale puis à un déficit microvasculaire et à des altérations de la perméabilité capillaire. Cet état entraîne une diminution des échanges entre les cellules, les fibres, et les vaisseaux et conduit peu à peu à une modification fibrinoide des fibres conjonctives, à une compression capillaire avec ralentissement circulatoire, et enfin à une surcharge des adipocytes en triglycérides. The clinical entity called cellulite is primarily seen as a consequence of polyendocrine changes. The pathogenesis seems to be linked to a hyperpolymerization of mucopolysaccharides and to fluid retention, leading to hyperviscosity of the fundamental substance then to a microvascular deficit and to alterations in capillary permeability. This state leads to a decrease in exchanges between cells, fibers, and vessels and gradually leads to a fibrinoid modification of the connective fibers, to capillary compression with circulatory slowing, and finally to an overload of adipocytes with triglycerides.
Cette situation conduit à la formation de micro puis de macronodules souscutanés qui donnent à la peau un aspect capitonné en "peau d'orange".This situation leads to the formation of micro then subcutaneous macronodules which give the skin a padded appearance in "orange peel".
De nombreux produits sont disponibles sur le marché, mais ces produits sont sans activité réellement prouvée. Une explication aux insuccès rencontrés pourrait être que les traitements disponibles s'intéressent et se limitent, dans la plupart des cas, à la pysiologie de l'adipocyte, puis éventuellement à l'amélioration de la circulation sanguine. Many products are available on the market, but these products have no proven activity. One explanation for the failures encountered could be that the treatments available are concerned with and are limited, in most cases, to the pysiology of the adipocyte, and then possibly to the improvement of blood circulation.
La présente invention repose sur une approche originale selon laquelle il est indispensable de prendre en compte et de traiter la rigidité de la trame conjonctivale. II est possible ensuite de rétablir la fonctionnalité de la microcirculation, puis en aval de la cascade des évènements, contribuer à l'activation de la lipolyse. The present invention is based on an original approach according to which it is essential to take into account and treat the rigidity of the conjunctival framework. It is then possible to restore the functionality of the microcirculation, then downstream of the cascade of events, to contribute to the activation of lipolysis.
Une solution est proposée par l'utilisation de thiols permettant une inhibition des ponts entre fibrilles de collagènes, ponts qui sont à l'origine de la rigidification du milieu et d'un emprisonnement des cellules adipeuses hypertrophiées. A solution is proposed by the use of thiols allowing an inhibition of the bridges between collagen fibrils, bridges which are at the origin of the stiffening of the medium and of a trapping of the enlarged adipose cells.
La présente invention a donc plus particuliérelent pour objet une composition cosmétique ou pharmaceutique pour la prévention et le traitement topique de la cellulite, comprenant à titre de principe actif une quantité efficace d'un thiol dans une base cosmétique ou pharmaceutique pour application topique. The present invention therefore more particularly relates to a cosmetic or pharmaceutical composition for the prevention and topical treatment of cellulite, comprising as active principle an effective amount of a thiol in a cosmetic or pharmaceutical base for topical application.
La présente invention a également pour objet un procédé pour la prévention et le traitement topique de la cellulite qui consiste à appliquer sur la peau une quantité efficace d'un thiol. The present invention also relates to a method for the prevention and topical treatment of cellulite which consists in applying to the skin an effective amount of a thiol.
Le thiol utilisé dans la présente invention est notamment choisi parmi le dithiothréitol, le dithioérythritol, la penicillamine, la cystéine et la N-acétylcystéine. Par thiol, on désigne des composés dont la fonction thiol est libre et non pas des thioéthers comme décrits dans FR
A-2 369 840.The thiol used in the present invention is chosen in particular from dithiothreitol, dithioerythritol, penicillamine, cysteine and N-acetylcysteine. The term “thiol” denotes compounds whose thiol function is free and not thioethers as described in FR
A-2,369,840.
Les compositions selon l'invention peuvent contenir de 0,01 à 5 % en poids de thiol. The compositions according to the invention can contain from 0.01 to 5% by weight of thiol.
Les compositions selon l'invention peuvent avantageusement contenir un agent favorisant la microcirculation. Comme agents de ce type, on peut citer des extraits de Ginkgo biloba, ruscus, mélilot, vigne rouge. The compositions according to the invention may advantageously contain an agent promoting microcirculation. As agents of this type, there may be mentioned extracts of Ginkgo biloba, ruscus, sweet clover, red vine.
Les compositions selon l'invention peuvent en outre contenir avantageusement un agent d'activation de la lipolyse. Comme agents de ce type on peut citer les extraits de Lierre terrestre (Glechoma), de racines d'Angélique, d'extrait de Paullinia, de maté ou encore des bases xanthiques telles que caféine, théobromine et théophylline. The compositions according to the invention may also advantageously contain an agent for activating lipolysis. As agents of this type, mention may be made of extracts from ground ivy (Glechoma), from Angelica roots, from Paullinia extract, from mate or also from xanthic bases such as caffeine, theobromine and theophylline.
Une composition préférée comprend de 0,01 à 5 % en poids de thiol, de 0,2 à 5 % en poids d'agent favorisant la microcirculation tel qu'un extrait de feuilles de ginkgo biloba, de 0,2 à 10 % en poids d'agent d'activation de la lipolyse. A preferred composition comprises from 0.01 to 5% by weight of thiol, from 0.2 to 5% by weight of agent promoting microcirculation such as an extract of ginkgo biloba leaves, from 0.2 to 10% by weight. weight of lipolysis activating agent.
Une composition particulièrement préférée comprend: de 0,01 à 5 % en poids de cystéine ou de N-acétylcystéine, de 0,2 à 5 % d'extrait de feuilles de Ginkgo biloba, de 0,2 à 5 % en poids d'extrait de Glechoma, de 0,2 à 5 % en poids d'extrait de Paullinia, de 0,01 à 0,5 % en poids d'extrait d'Angélique. A particularly preferred composition comprises: from 0.01 to 5% by weight of cysteine or of N-acetylcysteine, from 0.2 to 5% of extract of leaves of Ginkgo biloba, from 0.2 to 5% by weight of Glechoma extract, 0.2 to 5% by weight of Paullinia extract, 0.01 to 0.5% by weight of Angelica extract.
Le demandeur a découvert que la composition selon l'invention présente une remarquable activité anticellulitique et qu'elle peut s'opposer à l'installation des désordes lipodystrophiques chez l'être humain, notamment chez la femme. Une composition cosmétique ou pharmaceutique entrant dans le cadre de la présente invention a été testée dans plusieurs cas de cellulite de façon à vérifier le bien-fondé de cette nouvelle approche pharmacologique. The applicant has discovered that the composition according to the invention has a remarkable anticellulitic activity and that it can oppose the onset of lipodystrophic disorders in humans, in particular in women. A cosmetic or pharmaceutical composition falling within the scope of the present invention has been tested in several cases of cellulite so as to verify the merits of this new pharmacological approach.
L'étude présentée ci-après met en évidence l'activité anticellulitique d'une composition selon la présente invention. The study presented below demonstrates the anticellulitic activity of a composition according to the present invention.
La composition utilisée pour l'étude était la suivante:
Extrait sec de Glechoma hederacea 1,00 g
Extrait sec de Paullinia cupana 1,00 g
Extrait hydroglycolique de Ginkgo biloba 1,00 g
N-acétylcystéine 0,16 g
Huile essentielle d'Angélique 0,05 g
Parahydroxybenzoate de méthyle 0,15 g
Kathon CG 0,00075 g
Tween 80 1,50 g
Eumulgin L 0,50 g
Alcool 90 VN 2,00 g
Carbopol 940 0,80 g
Trolamine qsp pH = 6,5
Eau purifiée qsp 100 g.The composition used for the study was as follows:
Glechoma hederacea dry extract 1.00 g
Paullinia cupana dry extract 1.00 g
Ginkgo biloba hydroglycolic extract 1.00 g
N-acetylcysteine 0.16 g
Angelica essential oil 0.05 g
Methyl parahydroxybenzoate 0.15 g
Kathon CG 0.00075 g
Tween 80 1.50 g
Eumulgin L 0.50 g
Alcohol 90 VN 2.00 g
Carbopol 940 0.80 g
Trolamine qs pH = 6.5
Purified water qs 100 g.
Six femmes âgées de 29 à 51 ans, se plaignant de cellulite au niveau des cuisses sont engagées dans l'essai. Deux sites d'application de l'invention sont retenus. La cuisse gauche et la cuisse droite. Deux formules de gel sont préparées et réparties en deux séries de tubes, une série de tubes contient une composition inactive, I'autre série de tubes contient une composition selon l'invention. Le paramètre retenu est l'examen cellulitique avant et après traitement avec étude de l'évolution des capitons. Après tirage au sort convenable, sans dévoiler à quelle série appartiennent les tubes remis, les sujets reçoivent une quantité suffisante de gel de chaque série, I'un est destiné à être appliqué sur la cuisse gauche, I'autre sur la cuisse droite. II est demandé aux sujetsd'appliquer les préparations deux fois par jour,-pendant quatre semaines, en massage sur les zones à traiter, jusqu'à pénétration du gel. Six women, aged 29 to 51, complaining of cellulite in the thighs were enrolled in the trial. Two application sites of the invention are selected. The left thigh and the right thigh. Two gel formulas are prepared and divided into two series of tubes, one series of tubes contains an inactive composition, the other series of tubes contains a composition according to the invention. The parameter retained is the cellulitic examination before and after treatment with study of the evolution of the dimples. After a suitable draw, without revealing to which series the tubes given belong, the subjects receive a sufficient quantity of gel from each series, one is intended to be applied to the left thigh, the other to the right thigh. The subjects are asked to apply the preparations twice a day, for four weeks, by massaging the areas to be treated, until the gel has penetrated.
Les résultats rapportés sont obtenus après 4 semaines d'application.The reported results are obtained after 4 weeks of application.
Les résultats montrent que la composition selon l'invention a permis de réduire dans la totalité des cas étudiés les signes cliniques de cellulite et notamment l'induration due aux capitons et donc l'aspect en peau d'orange. Cet effet n'est pas observé du côté où est appliquée la formule inactive. The results show that the composition according to the invention has made it possible to reduce, in all of the cases studied, the clinical signs of cellulite and in particular the induration due to the dimples and therefore the appearance of orange peel. This effect is not observed on the side where the inactive formula is applied.
Les compositions cosmétiques ou pharmaceutiques selon l'invention peuvent en outre contenir éventuellement toutes les substances connues ayant des propriétés bienfaisantes sur les téguments et particuliérement pour leur activité cosmétique ou pharmaceutique dans les soins des peaux de toutes natures en particulier celles manifestant une tendance aux surcharges graisseuses et à la formation de cellulite. The cosmetic or pharmaceutical compositions according to the invention may also optionally contain all the known substances having beneficial properties on the integuments and particularly for their cosmetic or pharmaceutical activity in the care of skin of all kinds, in particular those manifesting a tendency to fatty overloads. and the formation of cellulite.
Elles peuvent contenir des antiseptiques, des comédolytiques, des antiséborrhéiques, des parfums, des conservateurs et des colorants. They may contain antiseptics, comedolytics, antiseborrheics, perfumes, preservatives and dyes.
Les compositions cosmétiques ou pharmaceutiques selon l'invention peuvent se présenter sous toutes les formes topiques utilisées en pharmacie ou en cosmétologie: crème ou gel en pots ou en tubes, lait, lotion en flacon de verre ou de plastique, en ampoules, microinjections ou en flacons doseurs, compresses imprégnées, emplâtres, patch-tests, timbres. The cosmetic or pharmaceutical compositions according to the invention can be in any topical form used in pharmacy or in cosmetology: cream or gel in jars or in tubes, milk, lotion in glass or plastic bottle, in ampoules, microinjections or in dosing bottles, impregnated compresses, plasters, patch tests, patches.
Pour chaque forme particulière, on a recours à des excipients appropriés. Ces excipients doivent avoir toutes les qualités habituellement demandées. A titre d'exemples, on peut citer: le propylène glycol, la glycérine, I'alcool cétylique, les polyols, les phospholipides mis dans des liposomes ou non, les huiles végétales, animales, minérales, les mouillants, les épaississants, stabilisants et émulsionnants couramment utilisés. For each particular form, appropriate excipients are used. These excipients must have all the qualities usually required. By way of examples, there may be mentioned: propylene glycol, glycerin, cetyl alcohol, polyols, phospholipids put in liposomes or not, vegetable, animal, mineral oils, wetting agents, thickeners, stabilizers and commonly used emulsifiers.
Les différentes formes cosmétiques ou médicamenteuses mentionnées cidessus sont obtenues selon les méthodes utilisées dans ce domaine. On donnera ci-après-deux autres exemples de composition cosmétique ou pharmaceutiques (en parties en poids):
Hydroqel alcoolique 1
Extrait de Glechoma 1,0
Extrait de Ginkgo 0,5
Extrait de Paullinia 1,0
Huile essentielle d'angélique 0,05
Cystéine 0,15
.Tween80 2,0
Alcool 2,0
Triéthylamine 0,5
Carbopol 940 1,0
Eau qsp 100
Hydrogel alcoolique 2 Extrait de Glechoma 1,0 . Extrait de Ginkgo 0,5 Extrait de Maté 1,0 . Huile essentielle d'angélique 0,05 .Cystéine 0,15 .Tween80 2,0 .Alcool 2,0 .Triéthylamine 0,5 .Carbopol 940 1,0 .Eau qsp 100. The various cosmetic or medicinal forms mentioned above are obtained according to the methods used in this field. Two other examples of cosmetic or pharmaceutical composition will be given below (in parts by weight):
Alcoholic hydroqel 1
Glechoma extract 1.0
Ginkgo extract 0.5
Paullinia extract 1.0
Angelica essential oil 0.05
Cysteine 0.15
.Tween80 2.0
Alcohol 2.0
Triethylamine 0.5
Carbopol 940 1.0
Water qs 100
Alcoholic hydrogel 2 Glechoma extract 1.0. Ginkgo extract 0.5 Mate extract 1.0. Angelica essential oil 0.05. Cysteine 0.15. Tween80 2.0. Alcohol 2.0. Triethylamine 0.5. Carbon 940 1.0. Water qs 100.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9608122A FR2750332B1 (en) | 1996-06-28 | 1996-06-28 | COMPOSITION FOR THE PREVENTION AND TOPICAL TREATMENT OF CELLULITE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9608122A FR2750332B1 (en) | 1996-06-28 | 1996-06-28 | COMPOSITION FOR THE PREVENTION AND TOPICAL TREATMENT OF CELLULITE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2750332A1 true FR2750332A1 (en) | 1998-01-02 |
| FR2750332B1 FR2750332B1 (en) | 1998-09-11 |
Family
ID=9493556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9608122A Expired - Lifetime FR2750332B1 (en) | 1996-06-28 | 1996-06-28 | COMPOSITION FOR THE PREVENTION AND TOPICAL TREATMENT OF CELLULITE |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2750332B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797765A1 (en) * | 1999-08-24 | 2001-03-02 | Saburo Uchikuga | Cutaneous slimming cosmetic containing amino acids, pantetheins, and phosphodiesterase inhibitors |
| WO2007016050A1 (en) * | 2005-07-28 | 2007-02-08 | Global Cosmeceutical Innovations, Llc | Composition and method for treating cellulite |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2369840A1 (en) * | 1976-11-08 | 1978-06-02 | Oreal | NEW COSMETIC COMPOSITION WITH SLIMMING AND ANTI-CELLULITIC ACTION |
| FR2440355A1 (en) * | 1978-10-31 | 1980-05-30 | Proter Spa | THIOLIC DERIVATIVES OF PROPIONAMIDOACETIC ACID FOR THE TREATMENT OF CELLULITE |
| EP0437840A1 (en) * | 1989-12-29 | 1991-07-24 | Freund Industrial Co., Ltd. | Aqueous solution containing ginkgo-leaf extract |
| EP0493151A1 (en) * | 1990-11-28 | 1992-07-01 | L'oreal | Slimming composition containing ginkgo biloba as alpha-2 blocker |
| WO1993004669A1 (en) * | 1991-08-30 | 1993-03-18 | The Procter & Gamble Company | Use of n-acetyl-l-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
| US5198465A (en) * | 1991-06-19 | 1993-03-30 | Dioguardi Francesco S | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen |
| WO1994004129A2 (en) * | 1992-08-26 | 1994-03-03 | Beiersdorf Ag | Cosmetic and dermatological sunscreen compositions containing thiols and/or thiol derivates |
| ES2049661A1 (en) * | 1992-10-09 | 1994-04-16 | Imbeal S A Lab | Anti-cellulite compsn - contains mixt seaweed, algae, ivy and broom, with preservative in a substrate of fatty material and water |
| WO1994014428A1 (en) * | 1992-12-22 | 1994-07-07 | Handelman, Joseph, H. | Reduction of hair growth employing sulfhydryl reactive compounds |
| WO1995034280A1 (en) * | 1994-06-15 | 1995-12-21 | The Procter & Gamble Company | Methods of lightening hyperpigmented regions in mammalian skin |
-
1996
- 1996-06-28 FR FR9608122A patent/FR2750332B1/en not_active Expired - Lifetime
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2369840A1 (en) * | 1976-11-08 | 1978-06-02 | Oreal | NEW COSMETIC COMPOSITION WITH SLIMMING AND ANTI-CELLULITIC ACTION |
| FR2440355A1 (en) * | 1978-10-31 | 1980-05-30 | Proter Spa | THIOLIC DERIVATIVES OF PROPIONAMIDOACETIC ACID FOR THE TREATMENT OF CELLULITE |
| EP0437840A1 (en) * | 1989-12-29 | 1991-07-24 | Freund Industrial Co., Ltd. | Aqueous solution containing ginkgo-leaf extract |
| EP0493151A1 (en) * | 1990-11-28 | 1992-07-01 | L'oreal | Slimming composition containing ginkgo biloba as alpha-2 blocker |
| US5198465A (en) * | 1991-06-19 | 1993-03-30 | Dioguardi Francesco S | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen |
| WO1993004669A1 (en) * | 1991-08-30 | 1993-03-18 | The Procter & Gamble Company | Use of n-acetyl-l-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
| WO1994004129A2 (en) * | 1992-08-26 | 1994-03-03 | Beiersdorf Ag | Cosmetic and dermatological sunscreen compositions containing thiols and/or thiol derivates |
| ES2049661A1 (en) * | 1992-10-09 | 1994-04-16 | Imbeal S A Lab | Anti-cellulite compsn - contains mixt seaweed, algae, ivy and broom, with preservative in a substrate of fatty material and water |
| WO1994014428A1 (en) * | 1992-12-22 | 1994-07-07 | Handelman, Joseph, H. | Reduction of hair growth employing sulfhydryl reactive compounds |
| WO1995034280A1 (en) * | 1994-06-15 | 1995-12-21 | The Procter & Gamble Company | Methods of lightening hyperpigmented regions in mammalian skin |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Section Ch Week 9419, Derwent World Patents Index; Class B04, AN 94-153280, XP002028530 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797765A1 (en) * | 1999-08-24 | 2001-03-02 | Saburo Uchikuga | Cutaneous slimming cosmetic containing amino acids, pantetheins, and phosphodiesterase inhibitors |
| WO2007016050A1 (en) * | 2005-07-28 | 2007-02-08 | Global Cosmeceutical Innovations, Llc | Composition and method for treating cellulite |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2750332B1 (en) | 1998-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2222303C (en) | Use of at least one no synthase inhibitor for treating sensitive skin | |
| EP0892642B1 (en) | Use in a composition of an extract of at least one labiate of the genus rosmarinarus, cultured in vitro | |
| CA2212101A1 (en) | Nitric oxide synthase inhibitors | |
| FR2746316A1 (en) | NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS | |
| CA2245123C (en) | Use of rosaceae plant extract as a bradykinin antagonist | |
| FR2695318A1 (en) | Topical compsn. for skin texture rejuvenation - contains arterial and capillary circulation stimulants | |
| CA2407294A1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
| FR2744017A1 (en) | ASSOCIATIONS OF PEROXIDIC LIPIDS AND ORGANOSILIC COMPOUNDS, COSMETIC AND DERMATOLOGICAL COMPOSITIONS CONTAINING SAME AND THEIR APPLICATIONS IN PARTICULAR FOR THE TREATMENT OF ALOPECIA | |
| BE1022152B1 (en) | COSMETIC COMPOSITION FOR PROMOTING GROWTH AND / OR BRAKING THE FALL OF HAIR | |
| WO2000030604A1 (en) | Composition for preventing and treating cellulitis | |
| FR2846555A1 (en) | Dermatological or cosmetic composition, useful e.g. for treating dry skin and protecting against allergens, contains a vinylpyrrolidone homopolymer and a copolymer based on phosphorylcholine | |
| EP0234143A1 (en) | Galenical forms based on fresh plants, and process for their preparation | |
| LU86396A1 (en) | COMPOSITIONS FOR THE TREATMENT OF Baldness and Alopecia | |
| FR2750332A1 (en) | Topical skin composition to treat or prevent cellulite | |
| FR2831440A1 (en) | COSMETIC COMPOSITION COMPRISING A DHEA DERIVATIVE AND A SOOTHING AGENT | |
| FR2758724A1 (en) | Controlling cellulite and fat deposition | |
| EP0277455A1 (en) | Hair composition | |
| FR2574289A1 (en) | NOVEL COSMETIC COMPOSITIONS FOR SCALP, COMPRISING A COMBINATION OF ACIDIC MUCOPOLYSACCHARIDES AND PEPTIDES, ASSOCIATED WITH PLACENT EXTRACT | |
| FR2620029A1 (en) | SURFACE LYMPHATIC VESSEL CARE PRODUCT | |
| EP0841893B1 (en) | Combination of zinc salicylate and a serenoa repens extract for treating seborrhoea, and cosmetic skin care compositions containing same | |
| FR2801789A1 (en) | Compositions comprise keratolin, a lipogenesis inhibitor and excipients for topical application, have a slimming effects on the face | |
| WO2004112743A2 (en) | Cosmetic care method combining a mechanical effect resulting from a massage, with complementary or relaying biological effects | |
| FR2882928A1 (en) | Cosmetic composition, useful to regenerate, restructure and stimulate derma, comprises palmitoyl-3-pentapeptide in combination with Centella asiatica extract | |
| FR2738486A1 (en) | Cell extracts from plant of Iridaceae family | |
| FR2823109A1 (en) | USE OF ALVERINE OR ONE OF ITS SALTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THEIR LOSS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| PLFP | Fee payment |
Year of fee payment: 20 |